PDCD1 and sarcoma: If confirmed in follow-up reports, our findings have profound implications for patient selection for anti-PD1 therapy and for ICI clinical trial design for sarcoma histologic subtypes that can originate in the dermis, such as undifferentiated pleomorphic sarcomas.